Get the latest news, insights, and market updates on TLSI (TriSalus Life Sciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
WESTMINSTER, Colo., November 18, 2025--TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the launch of the TriNav® XP Infusion System, the latest advancement in the company’s portfolio of pressure-enabled drug delivery systems designed to improve therapy delivery in varying vascular environments. Nov 18, 2025 - $TLSI
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
DENVER, November 13, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended September 30, 2025, and provides an operation update. Nov 13, 2025 - $TLSI
TriSalus (TLSI) Q3 2025 Earnings Call Transcript
Jeremy Feffer: Thank you, operator, and thank you all for participating in today's call. Joining me today from TriSalus Life Sciences, Inc. are Mary T. Szela, President and Chief Executive Officer, David B. Patience, Chief Financial Officer, and Dr. Richard Marshall, Medical Director. Ms. Szela will provide an overview of the company's third quarter results and strategy for the balance of the year. Nov 13, 2025 - $TLSI
Rockwell Medical (RMTI) Reports Q3 Loss, Lags Revenue Estimates
Rockwell Medical (RMTI) delivered earnings and revenue surprises of -25.00% and -5.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 12, 2025 - $TLSI
TriSalus Life Sciences to Participate in Upcoming Investor Conferences
WESTMINSTER, Colo., November 11, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the following investor conferences in November: Nov 11, 2025 - $TLSI
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
WESTMINSTER, Colo., November 10, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, November 12, 2025 at 10:00 AM ET featuring Nicole Lamparello, MD (Weill Cornell Medicine, New York-Presbyterian Hospital) and Francis Kang, MD (Universi Nov 10, 2025 - $TLSI
ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates
ICU Medical (ICUI) delivered earnings and revenue surprises of +31.82% and +3.66%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 7, 2025 - $TLSI
biote Corp. (BTMD) Tops Q3 Earnings and Revenue Estimates
biote Corp. (BTMD) delivered earnings and revenue surprises of +340.00% and +0.54%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 5, 2025 - $TLSI
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple